Contact Us
Drug Search Results
More Filters [+]

Necitumumab

Alternative Names: necitumumab, 11f8, imc-11f8, portrazza
Latest Update: 2024-08-05
Latest Update Note: Clinical Trial Update

Product Description

Necitumumab is a humanized IgG1 anti-EGFR. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30501503/)

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Canada | Croatia | European Medicines Agency | Germany | Greece | Hungary | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | Poland | Portugal | Slovenia | Spain | Sweden | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Necitumumab

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
UCLA L-08

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2025-12-02

Recent News Events

Date

Type

Title

09/26/2023

News Article

 Non-small Cell Lung Cancer Treatment Market Size 2023-2031

04/11/2023

News Article

 Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic

02/08/2023

News Article

 Global Desmoid Tumors Market to Surpass US$ 4,375.6 Million by 2030, Says Coherent Market Insights (CMI)

10/11/2022

News Article

 Global Non-small Cell Lung Cancer Treatment Market to Surpass US$ 50,962.7 Million by 2030, Says Coherent Market Insights (CMI)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions